TrialsgrambetaRCTs are beautiful

ATTR-ACT

2018

Tafamidis in Transthyretin Amyloid Cardiomyopathy

In 441 patients with transthyretin amyloid cardiomyopathy, tafamidis reduced all-cause mortality and cardiovascular hospitalisation compared with placebo.

Result

Efficacy: All-cause mortality + CV hospitalisationHR 0.7

Below 1 favours tafamidis, above 1 favours placebo.

Also reported: Fewer CV hospitalisations.

Original publication
Subtopic
Cardiomyopathy
Design
Double-blind RCT
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Maurer MS, et al. N Engl J Med. 2018;379(11):1007-1016.doi 10.1056/NEJMoa1805689

Discussion & critique

First disease-modifying therapy for ATTR cardiomyopathy. Survival curves separate only after ~ 18 months; cost and the need for early diagnosis limit reach.

Discussed in podcasts